SCHEMBL1287600

SCHEMBL1287600

CCc1oc2ccc(OC)cc2c1C(=O)c1ccc(OC)cc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 9/20 0.88
CYP2C9 P11712 2/20 0.67
EYA3 Q99504 2/20 0.65
KDM4E B2RXH2 3/20 0.59
ALDH1A1 P00352 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
MEN1 O00255 1/20 0.59
NPC1 O15118 1/20 0.59
LMNA P02545 1/20 0.59
MAPT P10636 1/20 0.59
RAB9A P51151 1/20 0.59
KMT2A Q03164 1/20 0.59
HSD17B10 Q99714 1/20 0.59
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CYP2C19 P33261 2/20 0.54
POLB P06746 1/20 0.52
GAA P10253 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1287502 0.94 SLC22A12 (1.00) SLC22A12CYP2C9EYA3KDM4EALDH1A1
SCHEMBL1287500 0.91 SLC22A12 (0.86) SLC22A12CYP2C9EYA3SMN1; SMN2MEN1
SCHEMBL1287903 0.90 SLC22A12 (0.72) SLC22A12CYP2C9EYA3KDM4EALDH1A1
SCHEMBL1287565 0.89 SLC22A12 (0.88) SLC22A12CYP2C9EYA3SMN1; SMN2MAPT
SCHEMBL1287462 0.86 CYP2C9 (0.83) SLC22A12CYP2C9EYA3KDM4EALDH1A1
SCHEMBL5711116 0.86 SLC22A12 (0.67) SLC22A12CYP2C9EYA3SMN1; SMN2LMNA
SCHEMBL1287521 0.85 SLC22A12 (1.00) SLC22A12CYP2C9EYA3ALDH1A1MEN1
SCHEMBL1287454 0.83 SLC22A12 (1.00) SLC22A12CYP2C9EYA3KDM4EALDH1A1
SCHEMBL1287515 0.83 SLC22A12 (0.86) SLC22A12CYP2C9EYA3SMN1; SMN2MEN1
SCHEMBL17969000 0.83 SLC22A12 (0.63) SLC22A12CYP2C9EYA3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action J-PHARMA CO., LTD. (JP) 2018-06-26 US disclosed
US-20130225673-A1 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION J-PHARMA CO., LTD. (JP) 2013-08-29 US disclosed
WO-2012048058-A2 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION J-PHARMA CO., LTD. (JP) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action SLCO2B1, SLCO2A1, SLC10A6 SLC22A12 19/4885CYP2C9 203/4885EYA3 4828/4885
US-20130225673-A1 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION SLCO2B1, SLCO2A1, SLC10A6 SLC22A12 19/4885CYP2C9 203/4885EYA3 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.